Clinical Trial Update: Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates on safety and efficacy of natural killer or memory T cell adoptive therapy for COVID-19 pneumonia with lymphopenia; phases 1/2 completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infection

Drugs mentioned

• NatuRal KillEr celLs or MEmory T Cells

Snippet

Sponsor: Instituto de Investigación Hospital Universitario La Paz | Conditions: Corona Virus Infection | Phase 1, Phase 2 | Status: COMPLETED